Contract analysis

I. EXECUTIVE SUMMARY The purpose of this memorandum is to request formal settlement authority from the Board of Directors of Optiwave Semiconductor Corp. ("OWS" or the "Company") for the patent infringement action captioned Optiwave Semiconductor Corp. v. Lumos Photonics, Inc., Case No. 5:22-cv-03417-EJD, currently pending in the United States District Court for the Northern District of California, San Jose Division,

II. PROCEDURAL BACKGROUND A. Case Posture OWS filed its Complaint for Patent Infringement on June 3, 2022, in the United States District Court for the Northern District of California, San Jose Division. The case was assigned to the Honorable Edward J. Torvelis and docketed as Case No. 5:22-cv-03417-EJD. The Complaint asserts infringement of four OWS patents directed to silicon photonics technologies:

1. U.S. Patent No. 10,234,567 (the "'567 Patent"), entitled "Integrated Waveguide Coupler with Adiabatic Mode Transition," issued March 19, 2019;

2. U.S. Patent No. 10,891,234 (the "'234 Patent"), entitled "Germanium-on-Silicon Photodetector with Graded Buffer Architecture," issued January 12, 2021;

3. U.S. Patent No. 11,045,678 (the "'678 Patent"), entitled "Multi-Channel Optical Transceiver with Integrated Wavelength-Division Multiplexing on a Monolithic Silicon Platform," issued June 29, 2021; and

4. U.S. Patent No. 11,312,890 (the "'890 Patent"), entitled "High-Speed Driver Circuit Architecture for Mach-Zehnder Modulator with Co-Integrated Pre-Emphasis Equalization," issued April 26, 2022. The accused products are Lumos's LumosBridge™ 800G Optical Engine and LumosEdge™ 400ZR+ Pluggable Transceiver, both of which are commercially significant products in Lumos's data center interconnect product line. These prod

III. IMPACT OF THE MARKMAN ORDER A. Summary of Constructions On February 17, 2023, the Court issued its Markman Order construing all eleven claim terms that were in dispute between the parties. The full text of the Order is attached as Appendix D. A summary of the Court's dispositions is as follows: The net effect of the Markman Order is that key claim limitations in all four asserted patents have been construed to e

1. The '567 Patent (Integrated Waveguide Coupler) The '567 Patent is directed to an integrated optical waveguide coupler that achieves low-loss mode transitions between different waveguide geometries through an adiabatic coupling mechanism. The patent claims a specific structural arrangement in which the coupling region transitions optical power from one waveguide mode to another gradually, avoiding the excitation of

2. The '234 Patent (Germanium-on-Silicon Photodetector) The '234 Patent is directed to a germanium-on-silicon photodetector structure that employs a graded buffer layer between the silicon substrate and the germanium absorber layer to manage lattice mismatch and reduce threading dislocation density. The critical limitation at claim construction concerned the composition profile of the buffer layer. The key disputed t

3. The '678 Patent (Multi-Channel Optical Transceiver with Integrated WDM) The '678 Patent is directed to a multi-channel optical transceiver architecture that integrates wavelength-division multiplexing (WDM) elements directly on a single silicon photonic integrated circuit (PIC). The patent claims a monolithic integration approach in which all optical and WDM components are fabricated within a single semiconductor

4. The '890 Patent (Driver Circuit Architecture for MZM) The '890 Patent is directed to a high-speed driver circuit architecture for a Mach-Zehnder modulator (MZM) in which a pre-emphasis equalization stage is co-integrated with the modulator on a common semiconductor substrate. The patent claims a design in which the driver and modulator share the same fabrication process and are electrically connected without the u

IV. LITIGATION SPEND TO DATE A. Calderwood & Harkness Fees and Costs Through the current date, C&H has billed a total of $1,847,312 in legal fees for its work in the Action. This figure reflects the blended hourly rate arrangement negotiated between C&H and OWS at the outset of the engagement, which includes a ten percent volume discount on C&H's standard hourly rates. The effective hourly rates for the primary billi

V. ESTIMATED COSTS OF CONTINUED LITIGATION A. Remaining Phase Costs (If Case Proceeds Through Trial) Should the Board determine not to authorize settlement and instead direct C&H to continue the prosecution of the Action through trial, the following cost estimates represent C&H's reasonable projections for the remaining phases of the litigation:

1. Completion of Fact discovery Remaining fact discovery includes supplemental document production (particularly Lumos's updated financial data for accused product revenues), depositions of Lumos technical witnesses — including Dr. Mei-Lin Chen (VP of Engineering, Silicon Photonics), Dr. Nikolai Petrov (Senior Director, Product Development), and potentially two to three additional engineering and sales personnel — an

2. Expert discovery Expert discovery would encompass the preparation and service of OWS's opening expert reports (Dr. Whitfield on infringement, Dr. Kessler on damages), the receipt and analysis of Lumos's responsive expert reports (anticipated from Dr. Raymond Ng, Lumos's technical expert, and Dr. Patricia Moreno of Compass Forensic Accounting LLP, Lumos's damages expert), the preparation and service of OWS's rebutt

3. Summary Judgment Briefing Lumos is virtually certain to move for summary judgment of non-infringement on all four patents based on the Markman constructions. OWS would need to brief its opposition to this motion, and Lumos would reply. The estimated cost for summary judgment briefing — including the substantial factual and legal work required to attempt to preserve any remaining infringement theory — is $200,000–$

4. Pre-Trial and Trial Preparation If any claims survive summary judgment (which C&H assesses as unlikely for three patents and possible but improbable for the '890 Patent), pre-trial preparation would include motions in limine, the preparation of the pre-trial order, jury instructions (or proposed findings of fact and conclusions of law for a bench trial), witness preparation, demonstrative exhibits, and related act

5. Trial The trial is currently projected as a five-to-seven-day patent bench trial before Judge Torvelis. Trial costs would include attorney time, witness coordination, demonstrative exhibit preparation, daily trial transcripts, and associated travel and logistics expenses. The estimated cost is $250,000–$350,000. Total estimated remaining costs to proceed through trial: approximately $1,550,000–$2,150,000. B. Risk

VI. SETTLEMENT OPTIONS AND ANALYSIS C&H has identified three primary options for the Board's consideration. Each option is analyzed below in terms of its proposed terms, advantages, disadvantages, and overall assessment. A. Option 1: Cross-License with Nominal Royalty (Preferred) Proposed Terms: • Mutual cross-license covering OWS's entire eighty-seven-patent portfolio and Lumos's patent portfolio (currently comprisi

VII. IMPACT ON OWS PATENT PORTFOLIO AND IP STRATEGY The Markman Order, while specific to this case and formally limited in its precedential effect, has broader implications for OWS's patent portfolio and intellectual property strategy that the Board should consider. Claim Drafting Vulnerabilities. The constructions adopted by the Court reveal potential drafting vulnerabilities in OWS's patent claims. Specifically, th

VIII. LENDER NOTIFICATION OBLIGATIONS OWS maintains a $40 million revolving credit facility with First Pacific Commerce Bank, N.A. ("FPCB") pursuant to the Amended and Restated Credit Agreement dated September 15, 2021 (the "Credit Agreement"). Section 6.03(d) of the Credit Agreement requires OWS to provide prompt written notice to FPCB of any "material litigation, arbitration, or regulatory proceeding" involving OWS

IX. RECOMMENDATION Based on the analysis set forth in this memorandum, C&H respectfully recommends that the Board of Directors grant Alan Ngo settlement authority as follows: Primary Objective: Pursue a cross-license agreement with Lumos on the following terms: a one-time royalty payment of $500,000 from Lumos to OWS; a mutual cross-license covering both parties' respective patent portfolios; a mutual covenant not to

X. REQUIRED BOARD ACTION C&H respectfully requests that the Board take the following actions:

1. Adoption of a formal resolution authorizing the settlement of Optiwave Semiconductor Corp. v. Lumos Photonics, Inc., Case No. 5:22-cv-03417-EJD, within the parameters described in Section IX of this memorandum, including (a) authority to pursue a cross-license with a nominal royalty of up to $500,000, and (b) fallback authority to accept a walk-away settlement with mutual releases and no monetary payment in either

2. Confirmation of concurrence by Vantage Point Capital Partners Fund IV, LP — which holds approximately 62% of OWS's equity through Vantage Point Capital GP IV, LLC — with the settlement authority requested herein. As the majority equity holder, Vantage Point's concurrence is both a practical necessity and a matter of good corporate governance, and C&H understands that Douglas Fairbanks III and Rebecca Torres, as re

3. Designation of Sandra Ellison, General Counsel, as the authorized signatory for OWS on any settlement agreement, mutual release, stipulation of dismissal, or other documents necessary to effectuate the settlement of the Action.

4. Board action by March 10, 2023, to permit prompt engagement with Lumos's counsel within the agreed-upon thirty-day settlement window. C&H notes that the settlement window is time-limited, and delay in obtaining Board authorization will reduce the time available for meaningful negotiations with Lumos. C&H is available to address any questions the Board may have regarding the contents of this memorandum, the litigat

XI. SIGNATURE Respectfully submitted, CALDERWOOD & HARKNESS LLP By: ________ Alan Ngo Partner, intellectual Property Group Registered Patent Attorney, USPTO Reg. No. 52,871 One Embarcadero Center, 34th Floor San Francisco, California 94111 Telephone: (415) 782-4127 Email: ango@calderwoodharkness.com Date: March 3, 2023 APPENDICES The following appendices are referenced in this memorandum and are either attached heret